羧酸酯酶1(CES1)多克隆抗體
Polyclonal Antibody to Carboxylesterase 1 (CES1)
ACAT; CEH; CES2; HMSE1; PCE1; SES1; TGH; Retinyl ester hydrolase; Serine esterase 1; Triacylglycerol hydrolase; Egasyn; Cocaine carboxylesterase; Liver Carboxylesterase 1
- 編號(hào)UPAC374Hu01
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源多抗制備
- 宿主兔
- 效價(jià)-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 RPC374Hu01-羧酸酯酶1(CES1)重組蛋白
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度500μg/mL
- 且適物種-
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 315 ¥ 735 ¥ 1050 ¥ 2625 ¥ 10500
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
DAB staining on IHC-P; Samples: Human Lung cancer Tissue; Primary Ab: 20μg/ml Rabbit Anti-Human CES1 Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19)
-
DAB staining on IHC-P;
Samples: Human Liver Tissue;
Primary Ab: 20μg/ml Rabbit Anti-Human CES1 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Samples: Human Stomach Tissue;
Primary Ab: 20μg/ml Rabbit Anti-Human CES1 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Human Liver Tissue
Primary Ab: 20μg/ml Rabbit Anti-Human CES1 Antibody
Control: Used PBS instead of primary antibody
Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Human Lung cancer Tissue
Primary Ab: 20μg/ml Rabbit Anti-Human CES1 Antibody
Control: Used PBS instead of primary antibody
Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Human Stomach Tissue
Primary Ab: 20μg/ml Rabbit Anti-Human CES1 Antibody
Control: Used PBS instead of primary antibody
Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19)
-
Figure. Western Blot; Sample: Recombinant CES1, Human.
-
Western Blot; Sample: U937 cell lysate
Primary Ab: 3μg/ml Rabbit Anti-Human CES1 Antibody
Second Ab: 0.2μg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)CES1的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別CES1。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UEPC374Hu61 | 羧酸酯酶1(CES1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPC374Hu01 | 羧酸酯酶1(CES1)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPC374Hu01 | 羧酸酯酶1(CES1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPC374Hu61 | 羧酸酯酶1(CES1)活性蛋白 | Cell?culture;?Activity?Assays. |
| UPAC374Hu01 | 羧酸酯酶1(CES1)多克隆抗體 | WB; IHC; ICC; IP. |
| USEC374Hu | 羧酸酯酶1(CES1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCC374Hu | 羧酸酯酶1(CES1)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMC374Hu | 羧酸酯酶1(CES1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| International Journal of Nanomedicine | Gold Nanoparticles Perturb Drug-Metabolizing Enzymes and Antioxidants in the Livers of Male Rats: Potential Impact on Drug Interactions [Pubmed: 32764932] |
